Neith Corporation (6236) Fair Value & Analysis
Healthcare · TW · Market cap 791M TWD
Fair value as of: Jun 24, 2026
Analysis
Neith Corporation (6236) currently trades at 19.00 TWD, while our model-based Fair Value estimate is 4.51 TWD — implying the stock looks roughly 76.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company provides nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; and other nutritional products under the King One name. It also offers genetic testing services. In addition, the company offers energy and dual-purpose mattresses, energy masks, energy silicon gel necklaces, energy waistbands, energy heating stones, massage rods, and water purifiers, as well as Ganbanyoku, an energy stone spa bed. Further, it offers beauty care products, such as cell regeneration and rejuvenation series skin care products; home energy products; and microcontrollers and peripherals. Neith Corporation was formerly known as Come True Biomedical Inc. Neith Corporation was incorporated in 1997 and is based in Taichung, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Neith Corporation (6236) undervalued?
What is the fair value of 6236?
What is the quality score of 6236?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.